About Us  |  Contact Us  |  Español
VNA of Care New England
VNA of Care New England

Merck Recalls Cholesterol Drug Liptruzet

Company issues recall due to defects in product packaging
TUESDAY, Jan. 14, 2014 (HealthDay News) -- Packaging defects have prompted a recall of the combination cholesterol drug Liptruzet, produced by Merck & Co., temporarily affecting the entire U.S. stock.
Merck said the foil pouches holding Liptruzet pills could allow air and moisture inside, potentially decreasing the drug's effectiveness. The recall covers all four dose strengths and every batch that's gone out since Liptruzet hit the market in May.
Liptruzet combines atorvastatin and Zetia (ezetimibe). Cardiologists expect no health problems to result from the recall, in part because both atorvastatin and Zetia will remain available separately.
"Patients are not going to be in any harm's way just going on atorvastatin until this packaging issue gets corrected," Kevin Marzo, M.D., chief of cardiology at Winthrop-University Hospital in Mineola, N.Y., told HealthDay.
Full Article (http://consumer.healthday.com/cardiovascular-health-information-20/dietary-choloesterol-news-130/merck-recall-cholesterold-drug-liptruzet-683861.html )
Health Headlines
Blood Test Might Help Prevent Certain Birth DefectsView in a lightbox
Adults Who've Abused Alcohol May Be at Risk for Memory ProblemsView in a lightbox
Annual COPD Costs To Hit $49 Billion by 2020: CDCView in a lightbox
Benefits of E-Cigarettes May Outweigh Harms, Study FindsView in a lightbox
Could a Blood Test Predict Suicide Risk?View in a lightbox
VNA of Care New England
© 2011 Site Index | Disclaimer | Legal Notices